Ekso Bionics Announces Reverse Stock Split Approval

EKSO BIONICS ( (EKSO) ) just unveiled an announcement.

On May 16, 2025, Ekso Bionics’ stockholders approved a reverse stock split at a 1-for-15 ratio, which will take effect on June 2, 2025. The split aims to increase the company’s stock price to meet Nasdaq’s minimum bid requirement, reducing the number of outstanding shares from approximately 35.5 million to 2.4 million.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Spark’s Take on EKSO Stock

According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral.

EKSO BIONICS’ overall stock score reflects the ongoing financial challenges and bearish technical indicators, which are partially offset by some positive developments from the latest earnings call. The company’s efforts to improve profitability and strategic partnerships offer potential upside, but the current financial and market conditions suggest caution. The valuation remains unattractive due to negative earnings, and the stock is currently experiencing downward pressure as indicated by technical analysis.

To see Spark’s full report on EKSO stock, click here.

More about EKSO BIONICS

Ekso Bionics is a leading developer of exoskeleton solutions designed to enhance human strength, endurance, and mobility for medical and industrial applications. Based in the San Francisco Bay Area, the company focuses on improving health and quality of life with advanced robotics and is listed on the Nasdaq Capital Market under the symbol ‘EKSO’.

Average Trading Volume: 2,064,858

Technical Sentiment Signal: Sell

Current Market Cap: $9.61M

See more insights into EKSO stock on TipRanks’ Stock Analysis page.